A Ligabue

Plain English
Researchers tested six different computational methods for measuring how easily aromatic molecules (ring-shaped carbon compounds) can be electrically polarized, using the most accurate method (CC3) as their gold standard to see which simpler methods worked best. They found that the CCSD method performed best overall, but surprisingly the SOPPA method outperformed the simpler CC2 method, suggesting scientists should use SOPPA instead for this type of work. The choice of mathematical basis set (the foundation of the calculation) mattered slightly more for frequency-dependent polarizabilities than static ones, but using the mid-sized aug-cc-pVTZ basis set gave reliable results without needing larger, more expensive calculations. The rankings held true even when they compared their calculations to real experimental measurements, meaning their conclusions about which methods work best will be useful for future research on similar molecules.

Plain English
Researchers studied five genes that help repair DNA damage and found hundreds of genetic mutations in the human population that should theoretically cause serious diseases—but they discovered that nobody actually has two copies of these broken genes, and nobody inherits multiple broken versions from different genes at the same time. This suggests that having two broken copies of these genes, or inheriting multiple different broken genes together, is so harmful that affected people cannot survive before birth or in early life. The findings explain why we see certain genetic diseases in patients who have defects in some of these genes, but not others—the missing diseases probably never occur in living people because they're incompatible with survival.

Plain English
Researchers discovered that a protein called Galectin-1 acts as a "glue" that holds together other proteins involved in cancer cell signaling, specifically by binding to Raf proteins and bringing them close to a cancer-causing protein called H-ras. They found that this scaffolding activity requires Galectin-1 to exist as a paired dimer and that blocking these connections prevents H-ras from forming the signaling clusters it needs to promote cancer growth. Why it matters: Since Galectin-1 is often overproduced in cancer cells and this study identifies exactly how it fuels cancer signaling, the connection points between Galectin-1 and Raf proteins could become new drug targets to stop cancer cells from growing.

Plain English
Researchers studied how certain rare mutations in a cancer protein called Ras make cells more likely to become tumors, even though these mutations don't dramatically boost the protein's activity in standard lab tests. They discovered that these mutations work by causing Ras to cluster more densely in tiny spots on cell surfaces, which makes the protein much more effective at triggering the growth signals that lead to cancer. This finding reveals a new way that cancer mutations can cause harm and suggests doctors might be able to fight these cancers by targeting how Ras clusters rather than trying to block its activity directly.

Plain English
Researchers created a new tool—a protein fragment that can detect GTP, a molecule that turns cancer-causing proteins on and off in cells. They used this tool to build a test that tracks whether Ras cancer proteins are active or inactive by measuring GTP levels in real time. This method works at extremely low protein concentrations and could help scientists discover new drugs to block cancer-causing Ras proteins.

Plain English
Researchers developed Dalton, a free computer program that predicts how electrons behave in molecules and calculates their chemical properties—like how molecules absorb light, respond to magnetic fields, and vibrate. The program works for molecules of any size, from small simple ones to large complex ones, and can run on multiple computers at once to handle the biggest calculations. Scientists use Dalton to understand molecular structure and predict chemical behavior without doing expensive lab experiments.

Plain English
Researchers developed a new test that measures how quickly GTPase proteins (molecular switches that control cell signaling) get loaded with GTP fuel and become active—a process that goes wrong in cancer and other diseases. The test uses a glowing marker attached to GTP that only shines when stuck to the protein, allowing scientists to watch the switching process happen in real time using tiny amounts of protein. This new method works in standard lab equipment and could help drug companies quickly screen thousands of compounds to find ones that fix broken molecular switches in cancer cells.

Plain English
Researchers studied how different versions of the H-ras protein arrange themselves into tiny clusters on cell membranes, and how this clustering affects whether the protein can activate downstream signaling molecules called Raf proteins. They found that the specific shape of the H-ras protein determines how it clusters, and that a helper protein called galectin-1 controls how many clusters form and how long they last—which directly controls whether Raf gets recruited and activated. This matters because mutations in the H-ras gene that cause cancer or developmental disorders might work partly by changing how the protein clusters on the membrane, not just by changing its shape—suggesting that doctors may need to look at clustering behavior to fully understand why certain mutations cause disease.

Plain English
Researchers tested berberine, a natural compound from plants, on ovarian cancer cells to understand how it kills cancer that has become resistant to the standard drug cisplatin. They found that berberine works by disrupting two critical processes the cancer cells need to survive: it blocks the folate cycle (which cells use to build DNA and proteins) and it disrupts polyamine metabolism (which cells need for growth), and it works especially well against drug-resistant cancers. The key finding is that berberine can restore drug sensitivity in resistant cancers—making previously untreatable cancer cells vulnerable to cisplatin again—suggesting it could be used alongside standard treatments to help patients whose cancers have stopped responding to chemotherapy.

Plain English
Researchers studied how a compound called Hoechst 33258 can block cancer cells from making too much thymidylate synthase protein—a protein that cancer drugs normally target—by directly binding to the messenger molecule that carries the instructions to build it. They found that this compound works by inserting itself into the genetic code near where protein production starts, preventing the cell from reading those instructions and making the protein, even though the genetic instructions themselves remain intact. This discovery matters because cancer cells often develop resistance to current drugs by making extra amounts of this protein, so this new approach could help overcome drug resistance and improve cancer treatment.

Plain English
Researchers studied how 5-fluorouracil, a cancer drug, causes cancer cells to produce more of an enzyme called thymidylate synthase—a protein that actually helps cancer cells survive the drug's attack. They found that this happens through three separate mechanisms: the drug turns on the gene that makes the enzyme, it traps cancer cells in a specific part of their growth cycle where this enzyme is normally made, and it prevents the enzyme from being broken down as quickly as usual. This matters because understanding exactly how cancer cells fight back against chemotherapy could help doctors combine 5-fluorouracil with other drugs in smarter ways to outsmart the cancer and make treatment more effective.

Plain English
Researchers studied how two proteins work together during DNA replication in a heat-loving bacterium: NucS (a protein that cuts DNA at specific spots) and PCNA (a protein that slides along DNA like a clamp during copying). They found that PCNA attaches to NucS and makes it better at recognizing and cutting DNA at the junctions where single-stranded and double-stranded DNA meet, while also making NucS more selective about where it cuts. This matters because understanding how these proteins team up reveals how cells control DNA cutting during replication, which is essential for proper cell division and could inform strategies for fighting diseases or engineering organisms.

Plain English
Researchers tested whether distamycin A and two modified versions of it could help cisplatin (a standard ovarian cancer drug) work better, especially in cancer cells that have become resistant to it. They found that distamycin A binds tightly to cancer cell DNA and shuts down certain enzymes that help cancer cells survive, while one modified version (NAX002) binds less tightly but works better when combined with cisplatin to kill resistant cancer cells. These findings matter because ovarian cancer cells often develop resistance to cisplatin, making treatment fail—but combining cisplatin with these distamycin compounds could potentially overcome that resistance and give patients another effective option.

Plain English
Researchers designed small protein fragments (peptides) that bind to a cancer-fighting enzyme called thymidylate synthase in a new location—at the junction where two copies of the enzyme stick together. These peptides shut down the enzyme by forcing it into an inactive form, which killed ovarian cancer cells in the lab, including cancer cells that had become resistant to standard platinum-based chemotherapy drugs. This matters because it offers a completely different way to attack thymidylate synthase than current cancer drugs do, potentially allowing treatment to work even when tumors have developed resistance to existing therapies.

Plain English
Researchers discovered a new enzyme called NucS that cuts branched DNA structures—the tangled, fork-like shapes that form when cells repair or copy their DNA. The enzyme works by teaming up with another protein called PCNA to recognize and cut at the exact spot where single-stranded DNA meets double-stranded DNA. This matters because cells need to clean up these branched structures quickly or they die, so understanding how NucS works could reveal new insights into how cells protect their genetic material.

Plain English
Researchers created a new platinum-based drug and tested it against two types of ovarian cancer cells: ones that respond to the standard drug cisplatin and ones that have become resistant to it. The new drug killed both types of cancer cells by damaging their DNA and disrupting critical cellular structures, though it attacked each type slightly differently—the sensitive cells died mainly from DNA damage and membrane breakdown, while the resistant cells died primarily from mitochondrial (cellular powerhouse) damage.

Plain English
Researchers used computer modeling to design new cancer-fighting drugs based on a chemical structure called triazolo-quinoxaline, then tested them to ensure they wouldn't poison healthy cells alongside tumor cells. They created a modified version of this drug that killed cancer cells effectively while being twice less toxic to normal cells than standard chemotherapy drugs like cisplatin and 5-FU. This matters because most cancer drugs are toxic to the body, so finding one that spares healthy cells while still fighting tumors could lead to safer cancer treatment.

Plain English
Researchers tested whether combining two types of cancer drugs—new folate inhibitors and polyamine-targeting drugs—could kill ovarian cancer cells better than either drug alone, including cancer cells that had developed resistance to cisplatin chemotherapy. The combination worked: it boosted a specific enzyme (SSAT) that destroys polyamines (molecules cancer cells need to survive), which killed cancer cells more effectively and even made drug-resistant cells responsive to treatment again. This suggests doctors could develop more effective ovarian cancer treatments by pairing these drugs together based on how they work through this SSAT mechanism.

Plain English
Researchers tested two new experimental drugs on ovarian and breast cancer cells, including ones that had become resistant to cisplatin (a standard chemotherapy). They found that cisplatin-resistant cancer cells were actually *more* sensitive to these new drugs than the original, non-resistant cells were. The resistant cells had higher levels of certain enzymes involved in cell division, and the new drugs were particularly good at shutting down these overactive enzymes—which is why the resistant cells died more easily when exposed to them. When the researchers combined the new drugs with cisplatin itself, they got even better results, especially when cisplatin was given first. This matters because cancers that become resistant to cisplatin are a major problem in treating ovarian cancer, and this research reveals a potential new strategy: using these novel drugs either alone or in combination with cisplatin to kill the resistant cancer cells that standard treatment can no longer stop.

Plain English
Researchers created six new platinum-based drugs designed to attach to cancer cell DNA and tested them against two types of ovarian cancer cells—one that responds to the standard drug cisplatin and one that has become resistant to it. The new drugs worked better when they had larger, greasier chemical structures (especially those with two phenyl groups), and importantly, they could still kill the resistant cancer cells even though those cells normally survive cisplatin treatment. Why it matters: This discovery could lead to new cancer treatments for patients whose tumors have become resistant to existing chemotherapy drugs.

Plain English
Researchers tested 990 elderly people to see which blood markers best predict insulin resistance (a condition where the body struggles to use insulin properly). They found that a protein called C3 is a much better predictor than three other commonly-used markers (CRP, white blood cell count, and ESR), and it remains predictive even after accounting for weight, cholesterol, and other factors. This matters because doctors currently rely on CRP and other markers to identify patients at risk for metabolic problems, but C3 is actually more reliable—so measuring C3 could help doctors better spot people who need early intervention to prevent diabetes and heart disease.

Plain English
Researchers developed a better mathematical method for calculating how nuclei in molecules shield themselves from magnetic fields—a property measured in NMR spectroscopy, which is used to determine molecular structure. They tested their new approach using two different computational methods (density functional theory and coupled cluster theory) and found it works as well as or better than existing methods, especially for molecules with complex electron behavior. This matters because more accurate predictions of these shielding values help chemists correctly interpret NMR data and confirm the identity and structure of unknown compounds without needing to perform expensive or time-consuming experiments.

Plain English
Researchers tested 713 elderly people in Italy to figure out why a heart failure blood marker called NT-proBNP varies so much between individuals, even when their hearts are healthy. They found that NT-proBNP levels rise when people have low red blood cell counts (which explains why women typically have higher levels) and drop when people have fatty livers—neither of which has anything to do with actual heart problems. This matters because doctors use NT-proBNP to diagnose heart failure, so they need to know that a person's blood count and liver fat can throw off the results and create false alarms or missed diagnoses in elderly patients.

Plain English
Chemists tested whether certain magnetic measurements could reliably identify aromatic compounds (stable ring-shaped molecules with special chemical properties). They found that these common magnetic measurements fail at this task, but a different measurement based on out-of-plane magnetic properties works better because it actually detects the circular flow of electrons that makes aromatic rings special.

Plain English
Researchers studied ovarian cancer cells that had become resistant to cisplatin, a common chemotherapy drug, and found that these resistant cells had low levels of a specific enzyme called SSAT. They boosted SSAT levels in the resistant cells and discovered this made them respond to cisplatin almost as well as non-resistant cancer cells do, especially when combined with an experimental spermine-based drug. The key finding is that restoring this one enzyme can reverse drug resistance in ovarian cancer, which could lead to a way to help patients whose tumors no longer respond to standard chemotherapy.

Plain English
Researchers used physics equations to explain why carbon atoms in benzene molecules respond the way they do when placed in a magnetic field, specifically modeling how the circular flow of electrons around the ring affects the carbon's magnetic properties. They found that while the electron currents directly under each carbon atom don't shield it from the magnetic field, the electron currents flowing around the other carbons in the ring contribute about 10% of the total shielding effect. This matters because it shows that classical physics equations can accurately predict how electrons in ring-shaped molecules behave magnetically, which helps scientists better understand molecular structure and design new materials.

Plain English
Researchers created a simple mathematical model to explain how magnetic fields cause electrons to circulate around ring-shaped molecules, using a physics principle called the Biot-Savart law. They tested their model against detailed computer calculations and found it accurately predicted how these electron movements affect the magnetic properties of atoms in the molecule. This work matters because it provides chemists with an intuitive way to understand and predict how ring-shaped molecules behave in magnetic fields, which is important for analyzing their structure using nuclear magnetic resonance.

Plain English
Researchers found that the classic explanation for why benzene repels magnets (based on electrons circling the ring) is incomplete because it doesn't account for all the electrons involved. When they used more advanced calculations that included more electrons, they discovered that benzene's electrons actually move in a more complex pattern—like a leap-frogging motion—rather than simple circular orbits, and this motion paradoxically makes benzene slightly attracted to magnets in certain directions instead of purely repelled. This matters because it means scientists need better mathematical models to truly understand how aromatic molecules (a huge category of organic compounds) behave around magnetic fields, which affects everything from drug design to materials science.

Plain English
Scientists calculated whether the fundamental forces that govern subatomic particles could cause chemical reactions to naturally favor making one specific "handed" version of a molecule (called the S version) over its mirror-image version (the R version). They found that these subatomic forces do create a tiny preference for the S version, both in the final product and during the reaction process itself. This matters because it could explain why life on Earth uses only certain "handed" versions of molecules—a mystery called homochirality—suggesting that the laws of physics themselves might have biased chemistry from the very beginning toward the molecular forms that life depends on.

Plain English
Researchers tested whether a blood marker called CA 242 could reliably identify pancreatic cancer by comparing it to two other commonly used blood markers in 276 people (46 with pancreatic cancer, plus people with other conditions and healthy controls). CA 242 identified pancreatic cancer in only 41% of cases, which was actually worse than the other two markers tested and didn't work any better when combined with them.

Plain English
Researchers tested whether a quick lab technique called NIRA could diagnose pancreatic fat malabsorption by measuring fat in single stool samples instead of requiring patients to collect stool for three days. They compared NIRA results to the traditional method in 120 patients with either pancreatic disease or other digestive problems. The technique worked well when measuring total fat output over three days, but performed poorly when using single-sample fat concentration—it couldn't reliably tell the difference between fat malabsorption caused by a failing pancreas versus other digestive disorders, even though pancreatic patients did have higher fat levels overall. The bottom line: NIRA can replace the old three-day collection method for measuring overall fat loss, but using it on quick spot samples isn't accurate enough to identify pancreatic problems specifically.

Plain English
Researchers measured two substances called endothelin-1 and endothelin-3 in the blood of patients with early-stage liver cirrhosis (before fluid buildup occurs) and compared them to healthy people, checking multiple times throughout the day to see how these levels changed and how they affected blood pressure and kidney function. They found that cirrhosis patients had consistently high levels of both endothelins throughout the day, unlike healthy people whose levels fluctuated slightly, but these elevated endothelins didn't appear to control blood pressure or damage kidney function the way researchers had suspected. This matters because it changes how doctors think about what causes problems in early cirrhosis—endothelin elevation alone isn't responsible for the blood pressure and kidney issues that develop, so treating endothelin might not be the key to preventing these complications.

Plain English
Researchers compared how the hearts and blood vessels of cirrhosis patients responded to body position changes versus healthy people, measuring heart function and hormone levels while standing and lying down. When cirrhosis patients lay down, their hearts pumped much faster and harder with less resistance from their blood vessels, while their stress hormones stayed abnormally high—a pattern that didn't happen in healthy controls or when the patients were standing. This matters because it shows that the heart problems in advanced cirrhosis get worse when patients lie down, likely because blood pools toward the center of their body and their blood vessels stop responding normally to the hormones that should make them constrict.

Plain English
Researchers treated 12 patients with severe liver disease and fluid buildup in their abdomen using a technique that removes the fluid, concentrates it, and puts it back into the bloodstream. The treatment temporarily increased the heart's pumping power and blood volume in the center of the body, but caused blood vessels throughout the body to dilate too much, which dropped blood pressure and canceled out any benefits. The temporary improvements in heart function and kidney performance disappeared within 48 hours, showing that this particular treatment doesn't provide lasting help for these patients' kidney problems or fluid retention—the very issues it was meant to address.

Plain English
Researchers studied how the kidneys handle salt in patients with advanced liver disease and fluid buildup (ascites) compared to healthy people, specifically testing what happens when patients lie down versus stand up. They found that when patients with liver disease stood up, their kidneys retained salt abnormally and their bodies produced high levels of hormones that promote salt retention. When these patients lay down, their kidneys did release more salt, but far less than in healthy people—and this happened because one salt-retaining hormone (aldosterone) remained too high relative to a salt-releasing hormone (atrial natriuretic factor), even though both changed in the right direction. This matters because it explains why patients with advanced liver disease and ascites cannot simply lie down to get rid of their excess fluid like healthier people can, pointing to a specific hormonal imbalance in the kidneys that prevents them from responding normally to body position changes.

Plain English
Researchers tested blood samples to understand how certain autoantibodies (proteins the immune system makes against the body's own thyroid) interfere with measuring thyroglobulin, a thyroid protein doctors use to monitor thyroid cancer patients. They found that simply measuring the level of these autoantibodies isn't enough to know whether they're actually interfering with the test—the same antibody level can cause very different amounts of interference in different people, varying up to tenfold. This matters because doctors need accurate thyroglobulin measurements to detect cancer recurrence, so labs need to run a special check on every single patient sample to catch when these antibodies are creating false results, rather than relying on antibody numbers alone.

Plain English
Researchers studied how the kidneys handle sodium in people with early-stage liver disease, comparing them to healthy people in different body positions. They found that when standing upright, liver disease patients' kidneys retained sodium abnormally due to high levels of the hormone aldosterone, but when the patients lay down, their kidneys released the sodium normally and matched the healthy controls' response. This matters because it explains why people with liver disease develop fluid buildup and swelling—their kidneys hold onto sodium when they're upright, and simply lying down can temporarily reverse this problem.

Plain English
Researchers compared how 13 liver disease patients (without fluid buildup) and 13 healthy people handled sodium when lying in bed for 24 hours on a controlled low-salt diet. The liver disease patients excreted roughly twice as much sodium in their urine despite having less sodium filtered through their kidneys, and this extra sodium loss was driven by higher levels of a hormone called ANP (atrial natriuretic peptide) rather than the typical sodium-conserving hormones. Why it matters: This finding suggests that liver disease patients have a built-in mechanism—through ANP—that forces them to shed excess sodium, which may actually help prevent them from developing dangerous fluid accumulation (ascites) that typically accompanies advanced liver disease.

Plain English
Researchers compared blood flow patterns in 10 patients with early-stage cirrhosis to 10 healthy people, measuring how their bodies responded to standing up versus lying down. When standing, cirrhotic patients and healthy controls showed no difference in blood pressure or blood volume markers, but when lying down, cirrhotic patients' hearts pumped significantly more blood and their blood vessels relaxed much more than in healthy people—suggesting their bodies were working harder to handle excess fluid that accumulated from their diseased livers. This matters because it explains how cirrhotic patients maintain normal blood pressure despite having too much blood volume: standing up distributes this excess fluid away from vital organs, but lying down causes it to rush back, forcing the heart to work harder and blood vessels to relax to prevent dangerous blood pressure spikes.

Plain English
Researchers compared how the hearts of cirrhosis patients and healthy people responded during exercise. They found that cirrhosis patients had weaker heart and blood pressure responses to exercise despite their bodies releasing more stress hormones—the opposite of what happens in healthy people. This matters because it shows cirrhosis damages how the heart responds to physical stress, which could explain why these patients have poor exercise tolerance and may be at risk during physical exertion.

Plain English
Researchers compared immune cells called neutrophils from heart attack patients to healthy people, finding that the heart attack patients' neutrophils were significantly weakened and slower to respond for at least three days after the attack. Under microscopic examination, these exhausted immune cells showed signs of being overworked and depleted, while healthy cells appeared normal and active. This matters because it explains why heart attack patients have impaired immune function during recovery, which could affect their ability to fight infection and heal properly after a heart attack.

Plain English
Researchers gave a beta-blocker drug (propranolol) to 17 liver cirrhosis patients with fluid buildup and measured how it affected their kidneys and stress hormone levels. The drug reduced the patients' stress hormones and improved how their kidneys filtered sodium, but only in patients who had abnormally high stress hormone levels at the start—those patients' kidney function actually improved significantly, while patients with normal stress hormone levels showed no change. This matters because cirrhosis patients often have kidney problems and fluid retention that are difficult to treat, and this finding suggests that beta-blockers might help specifically the subgroup of patients whose bodies are in overdrive from excessive stress hormones.

Plain English
Researchers tracked how kidneys handle salt and potassium in people with liver cirrhosis over a 24-hour period and found that their kidneys behave abnormally compared to healthy people—some retain too much salt while others mysteriously shed it, and this pattern doesn't follow the normal daily rhythm that healthy kidneys do. The hormone aldosterone, which normally controls salt and potassium balance, has much stronger effects in cirrhosis patients with fluid buildup (ascites), but a second problem—reduced salt reaching the kidney's potassium-handling units—prevents dangerous potassium loss that would otherwise occur. This matters because it explains why cirrhosis patients develop dangerous fluid retention and abnormal electrolyte levels, pointing toward aldosterone as a key target for treatment.

Plain English
Researchers measured stress hormone levels (norepinephrine) in blood and urine throughout the day in healthy people and patients with liver disease, finding that healthy people show a normal daily rhythm with higher levels in the morning and lower levels at night, while liver disease patients lost this rhythm entirely—their hormone levels stayed flat throughout the day regardless of disease severity. In healthy people, the stress hormone levels directly tracked with blood pressure and heart rate changes, but in liver disease patients this connection broke down, meaning their body couldn't properly coordinate these systems even when stable and not actively stressed. This matters because it shows liver disease damages the body's stress-response system early on, which could mean these patients won't respond normally to physical stress or emergencies, putting them at higher risk.

Plain English
Researchers tested whether three natural compounds called polyamines could boost the immune-fighting power of white blood cells called neutrophils. They found that polyamines significantly increased the cells' ability to produce superoxide (a toxic substance that helps kill bacteria) when the cells were activated by a bacterial chemical signal, but only when calcium was present in the environment. This matters because it reveals a new way that the immune system might ramp up its germ-killing power—polyamines appear to work by helping cells take in more calcium, which triggers a stronger immune response.

Plain English
Researchers tested 10 migraine patients while lying flat and then tilted upright to see how their bodies responded, measuring stress hormones and blood pressure both during an active migraine and during pain-free periods. When patients were actively experiencing a migraine, their bodies released fewer stress hormones and showed weaker blood pressure responses compared to healthy controls, suggesting their nervous system wasn't responding normally to the physical challenge. This matters because it shows that migraines involve a malfunction in the body's stress response system during an attack, which could help explain why migraines feel so disabling and might point to new ways to treat them.

Plain English
Researchers developed a simple, inexpensive test to measure a specific chemical called glycerol-3-phosphorylcholine in human semen, overcoming previous measurement problems by removing interfering substances that made results unreliable. The new test is accurate and recovers over 90% of the chemical being measured. Understanding this chemical matters because it affects the environment where sperm develop and may be important for male fertility, but scientists haven't been able to study it properly until now.

Plain English
When patients with cirrhosis (severe liver damage) and fluid buildup stand up or sit upright, their bodies release stress hormones that severely restrict kidney function and sodium excretion, while healthy people's kidneys handle posture changes without major problems. The researchers measured kidney function in 14 cirrhosis patients and 8 healthy people while they lay down and then sat up, finding that cirrhosis patients' kidneys dramatically reduced their ability to filter and excrete sodium in response to the body's stress hormone surge. This matters because understanding how posture triggers kidney problems in cirrhosis patients could help doctors manage these patients better and prevent dangerous complications like kidney failure and fluid accumulation.